News

• Aclarion Announces Participation at the NASS 37th Annual Meeting

  October 10, 2022

• John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

  October 3, 2022

• Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

  September 19, 2022

• Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

  August 4, 2022

• Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

  July 20, 2022

• Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

  June 22, 2022

• Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering

  April 27, 2022

• Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering

  April 22, 2022